Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the ...

Who wouldn't want to save a few extra bucks on their next flight purchase? While fares fluctuate based on a number of factors including demand, seasonality, and specific routes, there are some savvy ...

STOCKHOLM (Reuters) -Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Novo Nordisk (NVO) to $55 from $50 and keeps a Market Perform rating on the shares ahead of its Q3 results. In Wegovy, the CVS ...

(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and ...

(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and ...

Mr. Witt is the author of “The Thinking Machine,” a history of the A.I. giant Nvidia. He lives in Los Angeles. Oct. 10, 2025 How much do we have to fear from A.I., really? It’s a question I’ve been ...

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its ...